If you're at loose ends in DC today:
It’s a felony to compensate organ donors, but what counts as an organ is not always so clear. The stem cells contained in bone marrow are also present in the bloodstream, and are routinely extracted to be used in transplants to treat cancers and many blood and immune disorders. Should these cells be treated as an organ like bone marrow, or should the law permit compensation for blood stem cells just as it does for other non-invasive procedures like plasma or whole blood donation?
This a question the Health Resources and Services Administration is currently considering. With a substantial gap in the supply and demand for bone marrow transplants, particularly among racial minorities, how they choose to regulate will affect the lives of thousands of patients each year.
Join the Niskanen Center and the Georgetown Institute for the Study of Markets and Ethics for an expert panel on the legal, ethical and economic issues surrounding compensation for bone marrow, including:
Robert McNamara
Senior Attorney, Institute for Justice
Senior Attorney, Institute for Justice
Mario Macis
Associate Professor of Economics, Johns Hopkins Carey Business School
Associate Professor of Economics, Johns Hopkins Carey Business School
Peter Jaworski
Assistant Teaching Professor, Georgetown University
Assistant Teaching Professor, Georgetown University
Doug Grant
CEO, Hemeos
CEO, Hemeos
Samuel Hammond
Poverty and Welfare Policy Analyst, Niskanen Center
Poverty and Welfare Policy Analyst, Niskanen Center
Where:428a Russell Senate Office Building
Senate Committee on Small Business and Entrepreneurship Hearing Room
Senate Committee on Small Business and Entrepreneurship Hearing Room
When:
November 15 from 3:00-4:30pm
November 15 from 3:00-4:30pm
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.